Carisma Therapeutics ( ($CARM) ) has provided an update. On October 9, 2025, Carisma Therapeutics Inc. received a delisting determination letter ...

The clinical-stage biopharmaceutical company disclosed that its common stock will be suspended from trading on Nasdaq effective October 13, 2025, following previously disclosed noncompliance with ...

After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying off any staff “not deemed necessary to pursue strategic alternatives.” The ...

An announcement from Carisma Therapeutics ( ($CARM) ) is now available. Carisma Therapeutics Inc. announced plans to wind down its operations, ...

Sesen Bio and privately held Carisma Therapeutics are merging, with plans to combine into a “well-funded” biotech that will operate under Carisma’s name and work to advance its engineered macrophages ...

Carisma Therapeutics Inc. (CARM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Carisma Therapeutics Inc. (NASDAQ:CARM) shares are trading higher on Friday following the company’s announcement of a significant development in its collaboration with Moderna. What To Know: Carisma ...

PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Ocugen), a ...

"Following a comprehensive review of our portfolio, we have made the strategic decision to prioritize advancing our in vivo macrophage engineering platform," said Steven Kelly, President and Chief ...

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) Pre-clinical results showed that the novel in vivo anti-GPC3 ...

Carisma Therapeutics and Ocugen's subsidiary OrthoCellix have agreed to a reverse merger to create a new regenerative cell therapies subsidiary. The two companies said Monday in a joint statement that ...